Cardiac arrest and drug-related cardiac toxicity in the Covid-19 era. Epidemiology, pathophysiology and management

Επιστημονική δημοσίευση - Άρθρο Περιοδικού uoadl:3020659 30 Αναγνώσεις

Μονάδα:
Ερευνητικό υλικό ΕΚΠΑ
Τίτλος:
Cardiac arrest and drug-related cardiac toxicity in the Covid-19 era. Epidemiology, pathophysiology and management
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
SARS-CoV-2 (Covid-19) infection has recently become a worldwide challenge with dramatic global economic and health consequences. As the pandemic is still spreading, new data concerning Covid-19 complications and related mechanisms become increasingly available. Accumulating data suggest that the incidence of cardiac arrest and its outcome are adversely affected during the Covid-19 period. This may be further exacerbated by drug-related cardiac toxicity of Covid-19 treatment regimens. Elucidating the underlying mechanisms that lead to Covid-19 associated cardiac arrest is imperative, not only in order to improve its effective management but also to maximize preventive measures. Herein we discuss available epidemiological data on cardiac arrest during the Covid-19 pandemic as well as possible associated causes and pathophysiological mechanisms and highlight gaps in evidence warranting further investigation. The risk of transmission during cardiopulmonary resuscitation (CPR) is also discussed in this review. Finally, we summarize currently recommended guidelines on CPR for Covid-19 patients including CPR in patients with cardiac arrest due to suspected drug-related cardiac toxicity in an effort to underscore the most important common points and discuss discrepancies proposed by established international societies. © 2020
Έτος δημοσίευσης:
2020
Συγγραφείς:
Mavraganis, G.
Aivalioti, E.
Chatzidou, S.
Patras, R.
Paraskevaidis, I.
Kanakakis, I.
Stamatelopoulos, K.
Dimopoulos, M.-A.
Περιοδικό:
Food and Chemical Toxicology
Εκδότης:
Elsevier Ireland Ltd
Τόμος:
145
Λέξεις-κλειδιά:
amiodarone; azithromycin; chloroquine; disopyramide; dofetilide; dronedarone; flecainide; hydroxychloroquine; interferon; lopinavir plus ritonavir; mexiletine; propafenone; quinidine; remdesivir; sotalol; tocilizumab, acute coronary syndrome; acute heart infarction; Article; cardiomyopathy; cardiotoxicity; coronavirus disease 2019; diarrhea; disease transmission; drug potentiation; drug safety; electrolyte disturbance; epidemiological data; heart arrest; heart arrhythmia; heart failure; heart infarction; heart muscle conduction disturbance; heart muscle ischemia; hypokalemia; multiple organ failure; pandemic; pathogenesis; QT prolongation; respiratory failure; resuscitation; septic shock; short QT interval; Betacoronavirus; cardiotoxicity; complication; Coronavirus infection; heart arrest; heart arrhythmia; human; pathophysiology; prevention and control; virus pneumonia, Arrhythmias, Cardiac; Betacoronavirus; Cardiopulmonary Resuscitation; Cardiotoxicity; Coronavirus Infections; Disease Transmission, Infectious; Heart Arrest; Humans; Pandemics; Pneumonia, Viral
Επίσημο URL (Εκδότης):
DOI:
10.1016/j.fct.2020.111742
Το ψηφιακό υλικό του τεκμηρίου δεν είναι διαθέσιμο.